Sirtex Cover.proof 11 - School of Educators

More documents

Recommendations

Info

56 Reports on Patents Title: ‘Particulate Material’ SCHEDULE II Description: The invention relates generally to a particulate material which comprises hollow or cup-shaped ceramic microspheres having a diameter in the range of from 5 to 200 microns. The microspheres may be made radioactive and used in selective internal radiation therapy (SIRT) of various forms of cancer and tumours, including cancer of the liver. Specifically disclosed are radioactive microspheres which consist of yttria or another yttrium-containing compound as base material and in which the radionuclide is beta-radiation emitting yttrium-90. The scope of patent protection obtained in respect of the invention will be dependent on the scope of the claims which are granted in each national or regional patent. 1 Australian Patent Application No. 54724/94, dated 21 January 1994; lapsed, priority application for International Application No. PCT/AU95/00027. 2 International Application No. PCT/AU95/00027, dated 20 January 1995; lapsed, proceeding as national/regional applications set out below. 3 Australia – Application No. 690630, dated 20 January 1995; granted. 4 Canada – Application No. 2181254, dated 20 January 1995; pending. 5 Europe – Application No. 95906840.4, dated 20 January 1995; pending. 6 Japan – Application No. 519254/95, dated 20 January 1995; pending. 7 People’s Republic of China – Application No. 95191698.X, dated 20 January 1995; pending. 8 United States of America – Patent No. 5885547, dated 23 March 1999; granted. – Application No. 09/178259, dated 23 October 1998; allowed. 9 Hong Kong – Application No. 98113874.7, dated 17 December 1998; pending. Full details of the inventions which are the subject of the patents and patent applications set out in Schedules I and II are described in the relevant patent specifications. All of the patents and patent applications set out in Schedules I and II are currently in force, although some are subject to the payment of periodic (mainly annual) fees in order to maintain them in force. In most countries, a patent application is subjected to examination for novelty (and often obviousness) before a patent is granted. However, when a patent is granted, there can be no guarantee that the patent is valid and enforceable. Furthermore, there can be no assurance that each of the patent applications set out in Schedules I and II will result in the grant of a patent, or that the scope of protection provided by any patent which is granted will be identical to the scope of the application as originally filed. To date, there has been no third party challenge to the validity of any of the patents or patent applications set out in Schedules I and II. Davies Collison Cave acts as Patent Attorneys to Sirtex Medical, and for this reason has prepared this Report for inclusion in the Prospectus to be issued by Sirtex Medical. Davies Collison Cave will be paid its usual professional fees for the preparation of this Report based on commercial rates. It has no other interests in the promotion of Sirtex Medical. Yours faithfully DAVIES COLLISON CAVE John M. Slattery
Section 10Additional Information 57
Page 1 and 2:
S I R T E X M E D I C A L L I M I T
Page 3 and 4:
Chairman’s Letter Chairman’s Le
Page 5 and 6:
Section 2 1 The incidence of cancer
Page 7 and 8: Description of the Offer This Prosp
Page 9 and 10: • The extent of public and privat
Page 11 and 12: 4Section Industry Overview Sirtex M
Page 13 and 14: El-Serag and Mason (New England Jou
Page 15 and 16: 5Section Overview of Sirtex Medical
Page 17 and 18: Photograph of radioactive SIR-Spher
Page 19 and 20: Intellectual Property Position The
Page 21 and 22: Temp (c) 46 44 42 40 38 36 34 32 Th
Page 23 and 24: that has not been met with currentl
Page 25 and 26: 5.4.2 Costs of the Business The pro
Page 27 and 28: Manufacture of the SIR-Spheres will
Page 29 and 30: Board of Directors Dr Chris Roberts
Page 31 and 32: Section 7 Risk Factors 29
Page 33 and 34: Risk Factors Healthcare Funding Cha
Page 35 and 36: Section 8 Independent Accountants R
Page 37 and 38: Independent Accountants Report Duri
Page 39 and 40: Independent Accountants Report APPE
Page 41 and 42: Independent Accountants Report (e)
Page 43 and 44: Independent Accountants Report Cons
Page 45 and 46: Independent Accountants Report Cons
Page 47 and 48: Section 9 Reports on Patents 45
Page 49 and 50: Reports on Patents Patent Applicati
Page 51 and 52: Reports on Patents Date: 17 July 20
Page 53 and 54: Reports on Patents Patent Series 2
Page 55 and 56: Reports on Patents Trade Mark Serie
Page 57: Reports on Patents application unde
Page 61 and 62: Additional Information attaching to
Page 63 and 64: Additional Information Restricted s
Page 65 and 66: Additional Information Material Con
Page 67 and 68: Additional Information • approval
Page 69 and 70: Additional Information Executive Se
Page 71 and 72: Additional Information Consents and
Page 73 and 74: Additional Information of a directo
Page 75 and 76: Glossary of Terms and References Th
Page 77 and 78: Glossary of Terms and References Bu
Page 79 and 80: A B C E F Application Form SIRTEX M
Page 81 and 82: A B C E F Application Form SIRTEX M
Page 83 and 84: Design and Production: Downer Manci
show all

Sirtex Cover.proof 11 - School of Educators

Create successful ePaper yourself

Delete template?

Save as template?